A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Staphylococcus aureus Augments Epithelial Skin Barrier Damage Through T Cell Activation in Cutaneous T Cell Lymphoma




TekijätGluud, Maria; Pallesen, Emil M.; Zeng, Ziao; Namini, Martin R. J.; Vadivel, Chella Krishna; Gjerdrum, Lise Mette Rahbek; Yan, Lang; Ahmad, Sana; Lindahl, Lise M.; Bzorek, Michael; Kamstrup, Maria R.; Dey, Saptaswa; Ostrowski, Sisse Rye; Sorensen, Erik; Rantakari, Pia; Bonefeld, Charlotte Menne; Geisler, Carsten; Woetmann, Anders; Lahesmaa, Riitta; Iversen, Lars; Wolf, Peter; Litman, Thomas; Buus, Terkild B.; Odum, Niels

Julkaisuvuosi2026

Lehti: Allergy

ISSN0105-4538

eISSN1398-9995

DOIhttps://doi.org/10.1111/all.70292

Julkaisun avoimuus kirjaamishetkelläAvoimesti saatavilla

Julkaisukanavan avoimuus Osittain avoin julkaisukanava

Verkko-osoitehttps://onlinelibrary.wiley.com/doi/10.1111/all.70292

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/516087552

Rinnakkaistallenteen lisenssiCC BY

Rinnakkaistallennetun julkaisun versioKustantajan versio


Tiivistelmä
Background

Skin barrier dysfunction is central to inflammation and susceptibility to infection in atopic dermatitis (AD). Cutaneous T-cell lymphoma (CTCL) shares clinical similarities with AD and is also associated with a high prevalence of Staphylococcus aureus (S. aureus) colonisation. However, the mechanisms driving skin barrier damage in CTCL and the contribution of bacteria remain poorly understood.

Methods

We investigate how the interplay between S. aureus (and staphylococcal enterotoxins (SEs)) and primary malignant- and non-malignant T cells affects keratinocyte expression of skin barrier proteins; in vitro, in an EL4 murine lymphoma model of bacteria-driven tumour progression, and in CTCL patient lesions colonised with SE-producing S. aureus before and after bacterial eradication by antibiotic treatment.

Results

S. aureus and SEs activate malignant and non-malignant T cells to release barrier-repressing cytokines, including IL-4, IL-13, IL-22, and OSM, and JAK-dependent downregulation of filaggrin and loricrin in keratinocytes. In the EL4 model, bacteria-colonised tumour-bearing mice show significant filaggrin loss in tumour-adjacent epidermis, whereas antibiotic-treated mice maintain near-normal expression. Clinically, antibiotic eradication of SE-producing S. aureus partially restores filaggrin and loricrin expression in three of four patients, paralleling reduced inflammatory signalling.

Conclusions

SE-producing S. aureus promotes skin barrier impairment in CTCL through cytokine-driven, JAK-dependent repression of structural proteins in keratinocytes. These findings identify microbial–immune crosstalk as a contributor to CTCL skin pathology and provide mechanistic rationale for strategies targeting S. aureus colonisation as adjunctive therapy in CTCL.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Julkaisussa olevat rahoitustiedot
This research was funded by LEO Foundation through the LEO Foundation Skin Immunology Research Center, Dr. Abildgaard Fellowship (LF-FE-23-700015; T.B.B.), the Danish Cancer Society (Kræftens Bekæmpelse; C.K.V. and N.Ø.) the Fight Cancer Program (Knæk Cancer; R132-A8475; NØ) and donation from Fabrikant Vilhelm Pedersen og Hustrus Legat (Kræftens Bekæmpelse R374-A22434); Novo Nordisk Research Foundation (N.Ø.), Novo Nordisk Foundation Tandem Program—NNF210C0066950 in the call “Tandem Programme 2021” (N.Ø.), the Danish Council for Independent Research (Danmarks Frie Forskningsfond, grant number: 0134-00385B and grant https://doi.org/10.46540/3165-00211B; N.Ø.). RL was funded by Reserach Council of Finland grant 331793 and The Sigrid Jusélius Foundation. Role of the funding source: The funding source had no influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.


Last updated on